Topic: [ANN][INNBC]INNOVATIVE BIORESEARCH 💚 Funding AIDS cure research*get JDM cars 🚗 - page 5. (Read 17804 times)

Really nice blog post about INNBC Token sale, the first ICO developing novel AIDS cure research and with a Token backed by the value of actual physical goods.

http://vionaamaharani.blogspot.com/2018/05/innbcinnovative-bioresearch.html

Our ICO featured on Coingeeks

https://www.coingeeks.ru/innovative-bioresearch

New youtube review

https://www.youtube.com/watch?v=wRtHe_3EAsY

Please reffer to our FAQ, which you can find on the ICO page, for instructions on how to participate in the Token sale.

Any issue or question about the Token sale let me know.

So as our Token is spendable to buy jdm cars, we always monitor the market for these cars. So I just got back from a conversation with one of our contacts importing cars from Japan. The Subaru Impreza WRX Type RA LE just went up in value considerably in the recent months. Just a couple of months ago it was possible to buy one for 13k pounds, now they go for 20k pounds. This really shows that these cars are a very solid investment. Because our Token is backed by the value of these cars, this is going to preserve the INNBC Token value.

Unlike other coins that are backed just by hopes and dreams, and their price can go up and down to whatever value the market feels, our Token is backed by the value of real assets, and its price on exchanges should reflect that.

Any other question we are here to asnwer.

There is very poor funding with regard to exploring innovative solutions, take it from people who does this as a job .  So many promising projects are left unfunded by government agencies. This is why ICOs can be, without any doubt, a necessary and novel tool for funding potentially vital research that would have otherwise been left to die by the academic world.

Because governments can easily dictate what researches should be funded and developed, and because this process can also be influenced by possible conflicts of interests (e.g., pharmaceutical corporations selling HIV drugs not willing to lose their marketshare if an AIDS cure is developed), ICOs can be a necessary tool for our society to decentralize the funding power from government agencies/pharmaceutical corporations to the collectivity.

The INNBC Token will be accepted as a means of payment for all our furture medical services and products.

AIDS is currently one of the most threatening humans to the horror virus. There is no good therapy so far. Many medical experts have tried to solve the virus. Many countries’ governments have given a lot of financial support for research to overcome AIDS virus. If your project can solve this problem, ICO is not needed at all.

Summary of all yotube reviews we had thus far. It's a nice compilation showing great interested by the cryptocommunity

​https://www.youtube.com/watch?v=b74vb5zjq7E
https://www.youtube.com/watch?v=I2KUAyxpQwM
https://www.youtube.com/watch?v=ktPXafMlLmE
https://www.youtube.com/watch?v=EeKpIVSsRkQ
https://www.youtube.com/watch?v=KGR36O_ibEM
https://www.youtube.com/watch?v=5KIJhzIcoSU
https://www.youtube.com/watch?v=P2rhFOidtyA
https://www.youtube.com/watch?v=N6oGd9o9Epg
https://www.youtube.com/watch?v=hwMn5WKgEQI
https://www.youtube.com/watch?v=7SnQuaMtMes
https://www.youtube.com/watch?v=poyLH8ZKFhU
https://www.youtube.com/watch?v=qAQdVaJlExg
https://www.youtube.com/watch?v=8ETT4wy2HwI
https://www.youtube.com/watch?v=0nAcpyiee1A

New youtube review of our ICO!

https://www.youtube.com/watch?v=0nAcpyiee1A

New very nice article about our ICO

https://golos.io/bitcoin/@sofasharikova/innovative-bioresearch-platform-for-support-of-researches-in-the-sphere-searching-ways-treatment-aids-and-cancer

Guess what?  New youtube ICO review 

https://www.youtube.com/watch?v=8ETT4wy2HwI

Love these reviews.

Thanks. As the Token utility is directly related to the research, this should also make the Token skyrocket in value. Unlike other Tokens on the market for which the price is just the result of whatever the market feels, the INNBC Token is connected to a real business and as such is backed by real assets.

If your research will be successful, that is fantastic... good Luck

New youtube review of our ICO

https://www.youtube.com/watch?v=qAQdVaJlExg

Now, in the previous post I gave you a technical explanation about why our treatment is novel and is exploring approaches never tested before. However, there is also an economic explanation why there is such an extreme lack of innovation in this field.

There is the huge business of the pharmaceutical corporations selling expensive HIV drug, which aim to make as much profit as possible off of AIDS. These companies would never support the development of a low cost AIDS cure because it would put an end to their huge profits. This is precisely why we need a project such as this one in our society.

There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations.

Actually, we have conceived a very innovative cell-based therapy for HIV that uses the SupT1 cell line as a decoy target for the HIV virus. Our approach is unique as no other therapy tried to use a permissive T cell-line as a decoy target for the HIV virus. Furthermore, this is a cell-based approach, which is something completely different than traditional drug based approaches that failed to produce an AIDS cure. So we are not in need of inventing a new solution, we just need to further develop the HIV therapy we have already conceived, completing preclinical animal research and move to human trials. I'll post some information from our website regarding our novel AIDS therapy solution.


An Overview of SupT1 Cell Infusion Therapy, our Novel Cell-Based Therapy Solution for HIV
​

HIV infection usually leads to a progressive decline in number and functionality of CD4+ T lymphocytes, resulting in AIDS development. As explained in Jonathan Fior’s papers [1–3], the HIV virus has a higher tropism for SupT1 cells than for primary CD4+ T cells. Several hypotheses have been proposed as an explanation, most notably the higher surface expression of CD4 and CXCR4 receptors in SupT1 cells. In addition, in vitro studies of HIV evolution show that persistent growth in the SupT1 cell line results in a less cytopathic virus with a reduced capacity for syncytium formation, a higher sensitivity to neutralization, improved replication in SupT1 cells and impaired infection of primary CD4+ T cells [4–6]. Accordingly, Jonathan Fior proposed the infusion of irradiated SupT1 cells as a cell-based HIV therapy to exploit the therapeutic potential of these phenomena [1–3]. The rationale behind this approach is that moving infection toward the inoculated cells should prevent infection and depletion of the patient’s own CD4+ T cells and, therefore, AIDS. In such a strategy, SupT1 cells would act as a “decoy target” for the HIV virus to prevent CD4+ T cell depletion as well as to render the virus less cytopathic. As previously mentioned, in vitro studies of HIV evolution show that prolonged replication in SupT1 cells renders the virus less cytopathic and more sensitive to neutralization. Accordingly, replication of the virus in the inoculated SupT1 cells should also have a vaccination effect; that is, the therapy should also induce the virus to become progressively less aggressive and harmful for the patient. The use of SupT1 cells as a decoy target for HIV has been investigated in vitro and in vivo, with interesting results [1,3]. In vitro data showed that, when primary CD4+ T cells are infected with HIV in the presence of SupT1 cells, the preferential infection of SupT1 cells can spare primary CD4+ T cells from infection and depletion. In vivo data in humanized mice showed that significantly lower viral replication (~10-fold) and potentially preserved CD4+ T cell frequency at Week 1 was scored in animals treated with SupT1 cell infusion. Of note, one animal exhibited a sustained decrease in HIV replication and CD4+ T cell depletion (no virus detected anymore at Weeks 3 and 4), a result that may hold the key to future HIV treatments. Given the urgent and global need for a cost effective cure for HIV, we believe that the millions of people infected by this terrible disease deserve highly innovative HIV cure research strategies, such as SupT1 cell infusion therapy.

In summary, these are some of the potential therapeutic benefits of this cell-based treatment that go beyond what can be achievable with traditional antiretroviral therapy (cART):

1)The vaccination effect. As previously mentioned, SupT1 cells have been shown to have a very powerful vaccination effect in vitro [4–6]. In this regard, in vitro studies of HIV evolution showed that upon prolonged replication in SupT1 cells, the X4 HIV-1 LAI virus evolves toward a less virulent phenotype with a reduced capacity for syncytium formation, thus losing the main cytopathic feature characterizing X4 strains, and most notably the virus adaptation to replicate in SupT1 cells results in gradually losing the ability to replicate in primary CD4+ T cells [4]. In addition, the variation to neutralization sensitivity after viral growth in tumor T cell lines has also been examined. Interestingly, one study reported that primary isolates that were initially resistant to neutralization acquired sensitivity to neutralization after continuous growth in tumor T cell lines, and that the sensitivity to neutralization progressively increased during the days of culturing [5]. Specifically, it was shown that after 14 days in continuous culture, 100 micrograms/mL of rsCD4 (recombinant soluble CD4) were needed to neutralize 1 TCID of primary isolate, while only 0.3 micrograms/mL of rsCD4 were needed to neutralize 1 TCID of the virus after 75 days in continuous culture. This means that there was a 300 fold increase in virus sensitivity to neutralization after prolonged replication in a tumor T cell line, which is really something remarkable. All these phenomena could therefore harbor a significant therapeutic potential that could be exploited with SupT1 cell infusion therapy to induce HIV infection to evolve into a more tractable state for therapy.

2)Potentially no organ toxicity; cART is a drug based treatment and as such is associated with organ toxicity because the drugs are metabolized by various organs. By contrast, SupT1 cell infusion is a cell-based treatment and there is no chemical substance injected into the body that needs to be metabolized, which could significantly improve the quality of the patient's life.

3)Be effective in patients in a terminal state of disease that developed drug resistant and very aggressive HIV strains. When a patient is treated with cART, the virus fights back because it strives to survive, which can result in the development of very aggressive and drug resistant HIV strains, especially in the terminal stage of the disease and in such cases cART becomes ineffective. By contrast, SupT1 cell infusion therapy provides the virus with a permissive cell-line in which it can preferentially replicate, so that a peaceful coexistence between virus and host becomes possible, which could dramatically improve the patient's health as the virus infection progressively moves toward the inoculated SupT1 cells and the virus becomes increasingly less pathogenic for its host.

4)Possible association of the treatment with novel molecular compounds such as a Vif-inhibitor to act on HIV reservoirs. The HIV-1 Vif protein is essential for viral replication in primary CD4+ T cells but not in SupT1 cells [1]. Accordingly, pharmacologic inhibition of Vif could be combined with SupT1 cell infusion to further restrict viral replication to the inoculated SupT1 cells. Considering that APOBEC3G is expressed by different cell types, such as neuronal cells, astrocytes, and macrophages [2], pharmacologic inhibition of Vif may also have the benefit of acting on HIV reservoirs in the brain and other body areas. There are several molecules with promising anti-Vif activity currently being tested [2]. Similarly, other HIV-1 accessory proteins that are not essential for replication in SupT1 cells (e.g., Vpr, Vpu, and Nef [3]) may also be the target of pharmacologic inhibition. It is important to point out that these drugs would not affect virus replication in the inoculated SupT1 cells, and therefore in combination with SupT1 cell infusion therapy, there should not be development of drug resistance normally associated with drug based treatments.

​5)A cost effective AIDS cure solution. Our mission is to provide a cost effective cure solution for AIDS. In contrast with traditional cell-based and gene-based therapies that make use of modified autologous cells and are therefore very expensive and often unpractical for a large scale application, using a standardized T cell line such as the SupT1 cell line should significantly reduce the treatment costs associated with SupT1 cell infusion therapy, allowing access to the therapy where access to traditional HIV therapies is restricted by economic and social limitations. The social and economical impacts of a low cost HIV cure solution would be enormous.

Below some considerations with regard to potential issues:

1)Safety. We take this issue very seriously and are committed to performing very rigorous preclinical research to ensure there is enough data on safety to obtain approval from regulatory agencies for human experimentation. In this regard, injection of irradiated tumor cells as a therapy is already performed in cancer vaccination. In such cases, irradiating the cells prior to inoculation has been shown to ensure treatment safety both in animal and clinical studies [7]. We used the same protocol used in cancer vaccination studies (i.e., 30 Gy of radiation dose for the cells), which resulted in safe in vivo inoculation in our animal study as well [3]. Specifically, all animals successfully survived the treatment and presence of SupT1 cells was almost undetectable at late time points, which means that irradiating the cells prior to inoculation efficiently prevented SupT1 cell replication. Furthermore, we infused high doses of cells (40 million SupT1 cells were infused weekly), which in a highly immunodeficient mouse strain would rapidly lead to animal death in case of tumor development. Therefore, based on the clinical data we already have from cancer vaccination studies, and from the results of our first animal study, we believe that meeting the safety standards required for human trials is something feasible.

2)Rejection issues. Tumors can develop because tumor cells are able to evade immune recognition. For example, SupT1 cells do not express HLA-DR, which is an antigen highly associated with immune recognition [8]. Accordingly, given the tumoral nature of SupT1 cells, they should be significantly less immunogenic than normal cells and as such should survive in the patient long enough to provide a therapeutic effect. However, it is possible that the HIV virus will eradicate the cells faster and more efficiently than the immune system itself in any case.

References

1. Fior J. An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individuals. PLoS ONE. 2012;7:13.

2. Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5:753–757.

3. Fior, J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016, 4:13.

4. Das, A.T.; Land, A.; Braakman, I.; Klaver, B.; Berkhout, B. HIV-1 evolves into a nonsyncytiuminducing virus upon prolonged culture in vitro. Virology. 1999, 263:55–69.

5. Turner, S.; Tizard, R.; DeMarinis, J.; Pepinsky, R.B.; Zullo, J.; Schooley, R.; Fisher, R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 1992, 89:1335–1339.

6. Moore, J.P.; Burkly, L.C.; Connor, R.I.; Cao, Y.; Tizard, R.; Ho, D.D.; Fisher, R.A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses. 1993, 9:529–539.

7. Salgia R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 2003, 21:624–630.

8. Dufresne I, et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab′ fragments. Biochim Biophys Acta. 1999, 1421:284-94.

ICO now also listed on ICObuffer

https://icobuffer.com/projects/innovative_bioresearch

Amazing project